Study of Anti-CD33 Chimeric Antigen Receptor-Expressing T Cells (CD33CART) in Children and Young Adults With Relapsed/Refractory Acute Myeloid Leukemia
Running, not enrolling · Phase 1/Phase 2
Conditions studied: Acute Myelogenous Leukemia
In brief
This phase 1/2 trial aims to determine the safety and feasibility of antiCD33 chimeric antigen receptor (CAR) expressing T cells (CD33CART) in children and adolescents/young adults (AYAs) with relapsed/refractory acute myeloid leukemia (AML). The trial will be done in two phases: Phase 1 will determine the maximum tolerated dose of CD33CART cells using a 3+3 trial design, with dose-escalation for autologous products separated from dose-escalation for an allogeneic arm. Phase 2 is an expansion phase designed to evaluate the rate of response to CD33CART.
Key facts
- Study ID
- NCT03971799
- Run by
- Center for International Blood and Marrow Transplant Research
- People needed
- 52
- Starts
- 2020-01-08
- Expected to finish
- 2039-12-01
- Last updated by the study team
- 2025-07-14
Who can join
Age: 1 and older, up to 35. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Children's Hospital of Los Angeles — Los Angeles, California, United States
- Children's Hospital of Colorado — Aurora, Colorado, United States
- National Cancer Institute - NIH — Bethesda, Maryland, United States
- Dana-Farber Cancer Institute — Boston, Massachusetts, United States
- The Children's Hospital of Philadelphia — Philadelphia, Pennsylvania, United States
- Seattle Children's Hospital/Fred Hutchinson Cancer Research Center — Seattle, Washington, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.